Crispr Therapeutics Completes $600 Million Convertible Notes Offering
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Crispr Therapeutics AG ( (CRSP) ) just unveiled an announcement.
On March 16, 2026, CRISPR Therapeutics AG completed a $600 million private offering of Convertible Senior Notes due 2031, including the full exercise of a $50 million option, with an effective coupon of 1.125% that was increased to 1.7308% to offset anticipated Swiss withholding tax for ineligible holders. The company received net proceeds of approximately $585.2 million, which it plans to use for general corporate purposes, strengthening its liquidity to support ongoing operations and strategic initiatives.
The notes are senior unsecured obligations maturing on March 1, 2031, carry semiannual interest payments starting September 1, 2026, and are convertible into common shares at an initial rate implying a roughly 45% premium to the March 10, 2026 Nasdaq share price. The indenture sets detailed terms on conversion adjustments, optional redemption after March 6, 2029, fundamental change repurchase rights, and customary covenants and events of default, shaping investor protections and the company’s future capital structure flexibility.
The most recent analyst rating on (CRSP) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.
Spark’s Take on CRSP Stock
According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.
CRSP scores below average primarily due to highly volatile revenue, continued large losses, and persistent cash burn, which outweigh a relatively strong low-leverage balance sheet. Technically, the stock is trading below key moving averages, reinforcing weak near-term trend signals. Valuation is constrained by negative earnings (negative P/E) and no dividend, while recent pipeline progress and added financing capacity provide some support but not enough to offset the core financial and trend headwinds.
To see Spark’s full report on CRSP stock, click here.
More about Crispr Therapeutics AG
CRISPR Therapeutics AG operates in the biotechnology industry, focusing on gene-editing therapies based on CRISPR/Cas9 technology. The company develops treatments for serious diseases, targeting indications such as hemoglobinopathies, oncology, and other genetic disorders, and is listed on the Nasdaq Global Market, giving it access to international capital markets.
Average Trading Volume: 1,917,450
Technical Sentiment Signal: Sell
Current Market Cap: $4.68B
For detailed information about CRSP stock, go to TipRanks’ Stock Analysis page.
